Yahoo · Sep 2, 2026
Universe Pharmaceuticals Shares Rise 22.6% Premarket With No New Catalyst Identified
Universe Pharmaceuticals Inc (NASDAQ:UPC) shares rose 22. 6% to $5.
UP
NASDAQ · UPC
Universe Pharmaceuticals Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$4.46
Up+$0.30 (+6.73%)
Updated Sep 16, 2026, 9:16 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.35M
- P/E ratio
- 0.01
- Dividend yield
- 0.00%
- 52-week range
- $2.00 – $17.96
- Volume
- 60.14K
- Avg. volume
- 461.76K
Price performance
UPC price history
1M range · 20 trading sessions · Daily adjusted prices
UPC closed at $4.46 after 20 trading sessions, down 14.72% for the selected period.
- Last close
- $4.46
- Period change
- -14.72%
- Period low
- $3.88
- Period high
- $5.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $4.60 | $4.74 | $4.39 | $4.46 | 60.14K |
| Sep 14, 2026 | $4.27 | $4.82 | $4.27 | $4.81 | 173.28K |
| Sep 11, 2026 | $3.86 | $4.8394 | $3.7701 | $4.36 | 145.19K |
| Sep 10, 2026 | $4.05 | $4.05 | $3.80 | $3.88 | 16.47K |
| Sep 9, 2026 | $4.08 | $4.17 | $3.89 | $4.17 | 24.54K |
| Sep 8, 2026 | $3.93 | $4.40 | $3.93 | $4.20 | 39.78K |
| Sep 4, 2026 | $4.07 | $4.36 | $3.80 | $4.03 | 70.06K |
| Sep 3, 2026 | $4.44 | $4.90 | $4.26 | $4.33 | 124.36K |
| Sep 2, 2026 | $5.10 | $5.33 | $3.97 | $4.77 | 4.1M |
| Sep 1, 2026 | $4.6094 | $4.752 | $4.26 | $4.27 | 1.58M |
| Aug 31, 2026 | $4.78 | $5.01 | $4.58 | $4.58 | 13.34K |
| Aug 28, 2026 | $4.95 | $5.55 | $4.58 | $4.90 | 18.26K |
| Aug 27, 2026 | $5.21 | $5.50 | $4.6001 | $5.04 | 52.33K |
| Aug 26, 2026 | $5.03 | $5.91 | $5.03 | $5.32 | 96.87K |
| Aug 25, 2026 | $5.16 | $5.36 | $5.03 | $5.03 | 13.58K |
| Aug 24, 2026 | $5.29 | $5.36 | $5.11 | $5.36 | 19.47K |
| Aug 21, 2026 | $5.18 | $5.36 | $5.11 | $5.30 | 5.51K |
| Aug 20, 2026 | $5.26 | $5.45 | $5.03 | $5.33 | 17.51K |
| Aug 19, 2026 | $5.12 | $5.60 | $5.12 | $5.34 | 11.58K |
| Aug 18, 2026 | $5.56 | $5.61 | $5.21 | $5.23 | 29.85K |
Latest UPC news
The latest Smart Investors Daily articles mentioning UPC.
Stock researchCompany · Overview
UPC research
Overview
Company profile and research snapshot.
Company profile
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Sep 2, 2026
Stock Market Today: Dow Jones, S&P 500 Futures Rise, Nasdaq 100 Falls as US-Iran Tensions Escalate— DELL, PANW, MDB, AVGO in Focus (UPDATED)
U.S. stock futures declined on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 indices fell, following Tuesday's lower close.
Benzinga · Sep 2, 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS) shares
Benzinga · Sep 2, 2026
Universe Pharmaceuticals (UPC) Stock Soars Over 38% After-Hours: Here's What's Going On
Universe Pharmaceuticals Shares jumped after hours as eight investors disclosed ownership stakes following the company’s patent acquisition.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
